Antibody Drug Conjugates (ADCs)

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Antibody Drug Conjugates (ADCs)
Mar 12, 2025, 12:04 | Blog
Tanja Obradovic about the Growing Importance of Strategic Program and Pipeline Management in Pharma
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn: "Strategic…
Oct 25, 2024, 16:47 | Blog
Key milestones and insights from the evolution of antibody-drug conjugates - Zymeworks Inc.
Zymeworks Inc. shared a post on Linkedin: ''We're proud to share a recent publication in…
Sep 13, 2024, 12:06 | Blog
Aakash Desai: The biomarker landscape of ADCs and bispecific antibodies (BsAbs) in Lung cancer
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn: "Excited to share…
Sep 12, 2024, 19:20 | Blog
Herbert Loong: Join us at ESMO24 to discuss the emerging role of ADCs
Herbert Loong shared on LinkedIn: "Heading to Barcelona for ESMO24? Come join us on Saturday…
Jul 11, 2024, 10:12 | Blog
Shilpa Gupta: Stellar talk by Neeraj Agarwal on tremendous progress in mCRpC in Athens
Shilpa Gupta shared a post on X: “Stellar talk by Neeraj Agarwal on tremendous progress…
May 20, 2024, 11:14 | Drugs
AstraZeneca announces plans for a $1.5 billion manufacturing facility in Singapore for ADCs
AstraZeneca shared on LinkedIn: "We are excited to announce our plans for a $1.5 billion…
Apr 19, 2024, 07:31 | Drugs
Joseph Steward: Boston Consulting Group‘s overview of ADCs currently in clinical development
Joseph Steward, Freelance Medical and Scientific Writer, shared on LinkedIn: “Antibody-drug conjugates (ADCs) have become…
Apr 17, 2024, 11:33 | Drugs
Tanja Obradovic: What can we expect from antibody-drug conjugates (ADCs) in advanced ovarian cancer beyond Mirvetuximab?
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “What…
Apr 12, 2024, 05:16 | Drugs
Tanja Obradovic: Era of antibody drug conjugates just got even more exciting with the first tumor-agnostic approval for ADC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: "Era…
Feb 24, 2024, 16:34 | Blog
Chul Kim: What are other relevant targets for ADC therapy in NSCLC?
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter: "What are…
Jan 29, 2024, 13:37 | Blog
Sarah Sammons: Learning about Leptomeningeal Disease in Breast Cancer
Sarah Sammons, Breast Medical Oncologist at Dana-Farber's Breast Oncology Center, shared a post on X/Twitter:…
Jan 19, 2024, 18:00 | Blog
Prashant Mehta: My thoughts on developments in DLBCL management
Prashant Mehta, Senior Consultant and Assistant Professor in the Department of Medical Oncology/Hematology-oncology and Bone…
Dec 30, 2023, 17:51 | Opinion
Paolo Tarantino: Happy to have worked with Sarah Sammons and Nancy Lin at the ph2 DATO-Base trial
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared a post…
Dec 17, 2023, 17:26 | Blog
25 Posts Not To Miss From SABCS 2023
The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…
Oct 24, 2023, 14:57 | Blog
ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO) shared on LinkedIn: "Positive outcomes in advanced or metastatic…
All: 15 Posts: 1 - 100
Special Coverage